Onyx Scientific has announced a £1.5 million investment in its Sunderland facility to increase its GMP manufacturing capacity. More suites let Onyx ramp up commercial production while keeping the speed and flexibility its early phase clients need.
On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Chris Atherton, Commercial Director at Onyx Scientific, about the investment and what it means for Onyx's clients.
In this episode, Chris covers:
(00:53) Why more suite capacity lets Onyx meet its commercial clients' growing production needs without affecting the early phase clients who need flexibility and speed.
(01:46) The skilled people the investment relies on, across production, analytical, technician and warehouse roles.
(02:08) How commercial production, a fairly new step for Onyx since 2021 and the culmination of many years of work, is becoming routine manufacturing.
(02:38) Why small molecules remain the bedrock of drug development, and why Chris expects more early phase work over the next year or two as customers secure funding.
Watch the full episode to hear how the Sunderland investment supports Onyx Scientific's move into routine commercial manufacturing.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent/
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Chris Atherton
LinkedIn: https://www.linkedin.com/in/chris-atherton-471632111/
Ruby Collier
LinkedIn: https://www.linkedin.com/in/ruby-collier/
Timestamps:
00:00 Introduction
00:36 Commercial and early phase work
01:31 The skills behind the investment
02:23 Small molecule demand at CPHI Milan
03:19 Closing thoughts
#Newsbeat #ARTOTalent #CPHI #CPHIMilan #SmallMolecules #API #GMP #CDMO
","author_name":"ARTO Talent"}